Seirei Hamamatsu General Hospital | General Clinical Research Center
Status and phase
Conditions
Treatments
About
The purpose of this study is to investigate the efficacy and safety of NPC-12Y gel compared with placebo for skin lesions associated with tuberous sclerosis.
Full description
This is a Phase 3, placebo-controlled comparative study of NPC-12Y gel in patients with skin lesions associated with tuberous sclerosis complex. Patients who meet all entry criteria for this study will apply NPC-12Y gel or placebo twice a day for 12 weeks. After the double-blind evaluation period, all patients will apply NPC-12Y gel twice a day for 52 weeks. Approximately 40 eligible patients will be enrolled
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
43 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Norifumi Ishikawa
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal